De Novo ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis After COVID-19 mRNA Vaccination: A Case Report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho Heejin | - |
dc.contributor.author | Lee Hyun Soon | - |
dc.contributor.author | Kim Su Hyun | - |
dc.contributor.author | Shin Jungho | - |
dc.contributor.author | Hwang Jin Ho | - |
dc.date.accessioned | 2024-01-09T15:35:08Z | - |
dc.date.available | 2024-01-09T15:35:08Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.issn | 1598-6357 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/70676 | - |
dc.description.abstract | To prevent the spread of the coronavirus disease 2019 (COVID-19) pandemic, vaccines have been authorized for emergency use and implemented worldwide. We present a case of de novo glomerulonephritis (GN) after use of the COVID-19 mRNA vaccine BNT162b2.A 48-year-old man with no relevant medical history was referred for sudden and persistent worsening of renal insufficiency 1.5 months after the second vaccine dose. He had arthralgia and skin rash a week after vaccination. Abdominal pain and diarrhea started 2 weeks later, and he was admitted to the hospital for enteritis treatment. Colonoscopy showed multiple ulcerations and petechiae suggestive of vasculitis in the terminal ileum. After prednisolone therapy, his gastrointestinal symptoms improved, but his renal function continued to deteriorate. Based on kidney biopsy findings and nephrotic-range proteinuria (5,306 mg/24 hours), he was diagnosed with anti-neutrophil cytoplasmic autoantibody (ANCA)-negative pauci-immune crescentic GN (CrGN). He received high-dose steroid pulse therapy and oral cyclophosphamide, and then, gradually underwent steroid tapering, with improvement in proteinuria and renal function over several weeks. Several cases of GN suspected to be related to COVID-19 vaccines have been reported. To our knowledge, this is the first case report of ANCA-negative pauci-immune crescentic CrGN with extrarenal involvement after COVID-19 mRNA vaccination. Our finding expands the spectrum of COVID-19 vaccine-associated GN. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한의학회 | - |
dc.title | De Novo ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis After COVID-19 mRNA Vaccination: A Case Report | - |
dc.title.alternative | De Novo ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis After COVID-19 mRNA Vaccination: A Case Report | - |
dc.type | Article | - |
dc.identifier.doi | 10.3346/jkms.2023.38.e341 | - |
dc.identifier.bibliographicCitation | Journal of Korean Medical Science, v.38, no.41, pp 1 - 6 | - |
dc.identifier.kciid | ART003008296 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 001100305900003 | - |
dc.identifier.scopusid | 2-s2.0-85175356138 | - |
dc.citation.endPage | 6 | - |
dc.citation.number | 41 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | Journal of Korean Medical Science | - |
dc.citation.volume | 38 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Anti-Neutrophil Cytoplasmic Antibody | - |
dc.subject.keywordAuthor | Coronavirus Disease 2019 | - |
dc.subject.keywordAuthor | COVID-19 mRNA Vaccines | - |
dc.subject.keywordAuthor | Glomerulonephritis | - |
dc.subject.keywordAuthor | Pauci-Immune Vasculitis | - |
dc.subject.keywordPlus | VASCULITIS | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.